

NCT ID	NCT04595266
Title	Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
Phase	Phase 2
Date Added	2020-10-20
Location	Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT04589845
Title	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Phase	Phase 2
Date Added	2020-10-19

Location	Alabama, United States
	Arizona, United States
	California, United States
	Colorado, United States
	Delaware, United States
	Florida, United States
	Georgia, United States
	Idaho, United States
	Illinois, United States
	Indiana, United States
	Maine, United States
	Maryland, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Montana, United States
	Nebraska, United States
	Nevada, United States
	New Hampshire, United States
	New Jersey, United States
	New Mexico, United States
	New York, United States
	Ohio, United States
	Oregon, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Washington, United States
	Wisconsin, United States
	Australia
	Belgium
	Brazil
	Canada
	China
	Denmark
	France
	Germany
	Hong Kong
	Israel
	Italy
	Japan
	Korea, Republic of
	New Zealand
	Poland
	Portugal
	Puerto Rico
	Singapore
	South Africa
	Spain
	Switzerland
	Taiwan
	United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT04591431
Title	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Phase	Phase 2
Date Added	2020-10-19

Location	Italy
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib
Tags	MSS/ MMRp
NCT ID	NCT04575922
Title	Nivolumab+Ipilimumab+RT in MSS mCRC
Phase	Phase 2
Date Added	2020-10-05
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT04550897
Title	A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
Phase	Phase 1
Date Added	2020-09-16
Location	Norway
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BM7PE
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04535024
Title	The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
Phase	Phase 2
Date Added	2020-09-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT04483219
Title	Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
Phase	Phase 2
Date Added	2020-07-23
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status

Drugs	TKI ± anti-PD-1 antibody
Tags	MSS/ MMRp
NCT ID	NCT04444622
Title	Immunotherapy for Third Line Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2020-06-23
Location	Florida, United States Michigan, United States New Jersey, United States New York, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT04432857
Title	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Phase	Phase 1
Date Added	2020-06-16
Location	Missouri, United States Texas, United States Utah, United States Virginia, United States France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AN0025, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04426669
Title	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase	Phase 1, Phase 2
Date Added	2020-06-11
Location	Minnesota, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp